TY - JOUR
T1 - Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk
T2 - Subgroup Analysis of the Alliance A031203 CABOSUN trial
AU - George, Daniel J.
AU - Hessel, Colin
AU - Halabi, Susan
AU - Michaelson, M. Dror
AU - Hahn, Olwen
AU - Walsh, Meghara
AU - Picus, Joel
AU - Small, Eric J.
AU - Dakhil, Shaker
AU - Feldman, Darren R.
AU - Mangeshkar, Milan
AU - Scheffold, Christian
AU - Morris, Michael J.
AU - Choueiri, Toni K.
N1 - Publisher Copyright:
© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.
AB - Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.
UR - http://www.scopus.com/inward/record.url?scp=85070453089&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2019-0316
DO - 10.1634/theoncologist.2019-0316
M3 - Article
C2 - 31399500
AN - SCOPUS:85070453089
SN - 1083-7159
VL - 24
SP - 1497
EP - 1501
JO - Oncologist
JF - Oncologist
IS - 11
ER -